Data / Research funding / Hodgkin's Disease
Hodgkin's Disease: 48 NIH awards ($55.8M) to 31 organizations
48 NIH awards ($55.8M) in the NIH spending category Hodgkin's Disease, to 31 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- Topic
- NIH spending category
Awards
48 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| Hodgkin Lymphoma in PLWH in South Africa: TB, EBV, and Tumor Molecular Markers | NIH | National Cancer Institute | 2021 to 2024 | $3,536,890 | April 1, 2020 | September 30, 2025 | AMBINDER, RICHARD FREDERICK | reporter.nih.gov |
| B cell determinants of EBV latency (supplement) | NIH | National Cancer Institute | 2022 to 2025 | $3,376,443 | September 9, 2022 | August 31, 2027 | CESARMAN, ETHEL | reporter.nih.gov |
| Circulating Genomic Determinants of Treatment Failure in Hodgkin Lymphoma | NIH | National Cancer Institute | 2021 to 2025 | $3,211,729 | March 4, 2021 | February 28, 2026 | ALIZADEH, ASH ARASH | reporter.nih.gov |
| Modeling Multi-Source Data in Hodgkin Lymphoma | NIH | National Cancer Institute | 2022 to 2025 | $2,935,832 | March 1, 2022 | February 28, 2027 | PARSONS, SUSAN KENYON | reporter.nih.gov |
| Personalized Risk Prediction to Reduce Cardiovascular Disease in Childhood Cancer Survivors | NIH | National Cancer Institute | 2022 to 2025 | $2,933,453 | July 15, 2022 | April 30, 2027 | HOWELL, REBECCA MAUREEN | reporter.nih.gov |
| InterLymph Consortium: interrogating pleiotropy and gene by environment interactions among hematopoietic malignancies. | NIH | National Cancer Institute | 2021 to 2025 | $2,685,053 | September 3, 2021 | August 31, 2026 | MCKAY, JAMES DOWLING | reporter.nih.gov |
| Tumor suppressor reprogramming by EBV through post-translational modification | NIH | National Cancer Institute | 2022 to 2025 | $2,640,070 | September 1, 2022 | August 31, 2028 | ROBERTSON, ERLE S. | reporter.nih.gov |
| Tailoring CAR T cell therapy for Hodgkin Lymphoma | NIH | National Cancer Institute | 2021 to 2024 | $2,475,444 | July 1, 2020 | June 30, 2026 | SAVOLDO, BARBARA | reporter.nih.gov |
| Causal Representation Learning for the Spatial Analysis of Transcriptomic and Imaging Data in Tissue Contexts | NIH | National Center for Complementary & Integrative Health | 2022 to 2025 | $2,298,000 | September 15, 2022 | August 31, 2027 | UHLER, CAROLINE | reporter.nih.gov |
| Analysis and Therapeutic Targeting of the Linear-Ubiquitination Pathway in Hodgkin Lymphoma | NIH | National Cancer Institute | 2021 to 2025 | $2,108,871 | June 1, 2021 | May 31, 2027 | YANG, YIBIN | reporter.nih.gov |
| Investigating the EBV methylome in PLWH: Discovery and Development of Novel EBV Diagnostics in Plasma and Saliva | NIH | National Cancer Institute | 2023 to 2025 | $2,053,910 | September 8, 2023 | August 31, 2028 | AMBINDER, RICHARD FREDERICK | reporter.nih.gov |
| Role of novel onco-histone mutations in B-cell malignancies | NIH | National Cancer Institute | 2021 to 2023 | $1,967,972 | August 1, 2019 | July 31, 2025 | CESARMAN, ETHEL | reporter.nih.gov |
| Epstein-Barr virus LMP1 mediated oncogenicity | NIH | National Cancer Institute | 2021 to 2025 | $1,836,181 | September 19, 2019 | March 31, 2030 | GEWURZ, BENJAMIN ELISON | reporter.nih.gov |
| Role of Epstein-Barr virus LMP2A protein in maintaining oncogenic IgM signaling in EBV+ B cell lymphomas | NIH | National Cancer Institute | 2022 to 2025 | $1,746,152 | September 20, 2022 | July 31, 2027 | JOHANNSEN, ERIC C. | reporter.nih.gov |
| Gammaherpesvirus protein kinase: a master manipulator of the host during chronic infection. | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,730,785 | June 22, 2022 | May 31, 2028 | TARAKANOVA, VERA L. | reporter.nih.gov |
| Genetic pleiotropy across pediatric cancers, and cancer-related outcomes | NIH | National Cancer Institute | 2024 to 2025 | $1,395,864 | May 16, 2024 | April 30, 2029 | WANG, ZHAOMING | reporter.nih.gov |
| Roles of LMP1 and MYC in EBV-induced B-cell tumors | NIH | National Cancer Institute | 2023 to 2025 | $1,353,918 | September 1, 2023 | August 31, 2028 | KENNEY, SHANNON CELESTE | reporter.nih.gov |
| Targeting EBV-associated lymphomas | NIH | National Cancer Institute | 2024 to 2025 | $1,290,024 | September 10, 2024 | August 31, 2029 | DAMANIA, BLOSSOM A | reporter.nih.gov |
| Stringent Latent Epstein-Barr Virus (EBV) Infection Collaborates with Cellular Gene Alterations to Induce EBV+ Lymphomas | NIH | National Cancer Institute | 2023 to 2025 | $1,247,765 | July 1, 2023 | June 30, 2028 | KENNEY, SHANNON CELESTE | reporter.nih.gov |
| Remodeling of the host epigenome during EBV infection | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,096,596 | June 7, 2024 | April 30, 2029 | TEMPERA, ITALO | reporter.nih.gov |
| RPMS1 circular RNAs in EBV malignancies | NIH | National Cancer Institute | 2021 to 2023 | $1,083,260 | June 1, 2019 | May 31, 2024 | FLEMINGTON, ERIK K | reporter.nih.gov |
| COG NCTN Integrated Translational Science Center for Hematopoietic Malignancies in Children | NIH | National Cancer Institute | 2021 | $800,000 | April 18, 2019 | February 28, 2022 | MESHINCHI, SOHEIL | reporter.nih.gov |
| EBV LMP1/LMP2A Proteins Promote Hodgkin-like Lymphomas in Humanized Mice | NIH | National Cancer Institute | 2021 to 2022 | $755,384 | June 13, 2018 | August 31, 2023 | KENNEY, SHANNON CELESTE | reporter.nih.gov |
| Defining the Biological and Mechanistic Implications of XPO1 Mutations in Hematologic Malignancies | NIH | National Cancer Institute | 2021 to 2023 | $702,046 | August 1, 2018 | January 31, 2024 | TAYLOR, JUSTIN | reporter.nih.gov |
| Aging-Related Biomarkers of Neurocognitive Function in Long-term Hodgkin Lymphoma Survivors | NIH | National Cancer Institute | 2022 to 2024 | $655,112 | January 3, 2021 | June 30, 2026 | WILLIAMS, ANNALYNN | reporter.nih.gov |
| Deep Sequencing of Relapse and Refractory Hodgkin Lymphoma Genomes: A Study of Tumor Biology and Evolution | NIH | National Cancer Institute | 2023 to 2025 | $583,092 | September 1, 2023 | August 31, 2026 | GOMEZ, FELICIA | reporter.nih.gov |
| Investigating personalized approaches to de-intensify therapy for nodular lymphocyte-predominant Hodgkin lymphoma | NIH | National Cancer Institute | 2024 to 2025 | $569,568 | August 1, 2024 | July 31, 2029 | BINKLEY, MICHAEL S | reporter.nih.gov |
| CD25-mediated feedback control of BCR-signaling and its oncogenic mimics | NIH | National Cancer Institute | 2021 to 2022 | $549,899 | January 1, 2021 | May 31, 2023 | MÜSCHEN, MARKUS | reporter.nih.gov |
| Epstein-Barr Virus Nuclear Protein B Cell Growth Transformation | NIH | National Cancer Institute | 2021 | $532,500 | June 1, 1987 | July 31, 2022 | ZHAO, BO | reporter.nih.gov |
| Systematic CRISPR Analysis of EBV Lymphoma Resistance Pathways to Natural Killer Cell Lysis | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $492,250 | July 5, 2024 | May 31, 2026 | GEWURZ, BENJAMIN ELISON | reporter.nih.gov |
| Cardiopulmonary function and cerebral blood flow in Hodgkin Lymphoma survivors | NIH | National Cancer Institute | 2024 to 2025 | $452,634 | January 8, 2024 | December 31, 2026 | PHILLIPS, NICHOLAS S | reporter.nih.gov |
| Epstein-Barr virus nuclear antigen 2 in transcription regulation | NIH | National Institute of Dental & Craniofacial Research | 2025 | $450,462 | August 13, 2025 | May 31, 2030 | WANG, CHONG | reporter.nih.gov |
| From friend to foe: proviral role of IRF-3 in chronic gammaherpesvirus infection | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $439,665 | January 19, 2024 | November 30, 2026 | TARAKANOVA, VERA L. | reporter.nih.gov |
| Characterizing single cell states of activated and transformed B cells in rhesus macaque models | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $433,852 | March 2, 2023 | February 28, 2026 | SKALSKY, REBECCA L | reporter.nih.gov |
| Discovery of inhibitors of EBV lytic cycle inducing protein ZTA for therapeutic development | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $399,278 | August 16, 2022 | July 31, 2024 | YANO, TAKAHIRO | reporter.nih.gov |
| Determining Barriers Leading to Inferior Survival for Black and Hispanic Patients with Hodgkin Lymphoma: A Patient-Centered Study | NIH | National Cancer Institute | 2025 | $384,340 | February 1, 2025 | November 14, 2025 | MAILHOT, RAYMOND B | reporter.nih.gov |
| IRF-1: a brake to limit gammaherpesvirus infection and pathogenesis | NIH | National Cancer Institute | 2021 | $365,250 | December 5, 2016 | February 28, 2023 | TARAKANOVA, VERA L. | reporter.nih.gov |
| Advancing novel therapeutics and translational science to close the survivorship gap in pediatric, adolescent and young adult (AYA) lymphoma | NIH | National Cancer Institute | 2024 to 2025 | $357,818 | August 9, 2024 | July 31, 2029 | CASTELLINO, SHARON MARIE | reporter.nih.gov |
| Hodgkin’s Lymphoma-induced Nephrotic Syndrome | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2025 | $343,650 | January 1, 2025 | November 30, 2029 | MOLINA JIJON, EDUARDO | reporter.nih.gov |
| Aging-Related Biomarkers of Neurocognitive Function in Long-term Hodgkin Lymphoma Survivors | NIH | National Cancer Institute | 2021 to 2022 | $246,776 | January 3, 2021 | June 30, 2022 | WILLIAMS, ANNALYNN | reporter.nih.gov |
| NexTGen - ICR | NIH | National Cancer Institute | 2022 to 2023 | $230,695 | June 22, 2022 | May 31, 2025 | RABBITTS, TERRY | reporter.nih.gov |
| The Genetic Study of Families with a High Frequency of Hematopoietic Malignancy | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2022 | $213,287 | May 1, 2021 | September 1, 2023 | FLERLAGE, JAMIE ELIZABETH | reporter.nih.gov |
| Reprogramming myeloid cells by JAK inhibition to enhance checkpoint blockade therapy | NIH | National Cancer Institute | 2025 | $183,600 | September 1, 2025 | August 31, 2028 | ZAK, JAROSLAV | reporter.nih.gov |
| Resolving viral oncoprotein control of terminal cell fates to limit Epstein-Barr virus-driven lymphoproliferation | NIH | National Cancer Institute | 2025 | $183,044 | February 3, 2025 | January 31, 2028 | SORELLE, ELLIOTT DANIEL | reporter.nih.gov |
| Treatment Modifications, Outcomes and Provider Decision Making in the Management of Subsequent Breast Cancers Among Survivors of Childhood Cancer | NIH | National Cancer Institute | 2021 | $178,354 | September 17, 2018 | February 28, 2023 | TURCOTTE, LUCIE MARIE | reporter.nih.gov |
| Understanding the pathogenesis of classic Hodgkin lymphoma in persons living with HIV through conventional and spatial transcriptomics | NIH | National Cancer Institute | 2024 | $176,000 | August 8, 2024 | July 31, 2026 | NARESH, KIKKERI | reporter.nih.gov |
| Epstein-Barr virus and B-cell co-opted functions of the endogenous retrovirus envelope protein, Syncytin-1 | NIH | National Institute of Dental & Craniofacial Research | 2021 to 2022 | $84,564 | September 13, 2021 | September 12, 2023 | FREY, TIFFANY | reporter.nih.gov |
| InterLymph: At the Forefront of International Lymphoma Research | NIH | National Cancer Institute | 2022 | $12,000 | September 2, 2020 | August 31, 2023 | CAMP, NICOLA J. | reporter.nih.gov |
Organizations
| Organization | Place | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|---|
| Johns Hopkins University | Baltimore, MD | 2 | $5.6 million | 0 | $0 |
| Weill Medical Coll of Cornell Univ | New York, NY | 2 | $5.3 million | 0 | $0 |
| University of Wisconsin-Madison | Madison, WI | 4 | $5.1 million | 0 | $0 |
| Stanford University | Stanford, CA | 2 | $3.8 million | 0 | $0 |
| Univ of North Carolina Chapel Hill | Chapel Hill, NC | 2 | $3.8 million | 0 | $0 |
| Tufts Medical Center | Boston, MA | 1 | $2.9 million | 0 | $0 |
| University of TX MD Anderson Can CTR | Houston, TX | 1 | $2.9 million | 0 | $0 |
| Brigham and Women's Hospital | Boston, MA | 3 | $2.9 million | 0 | $0 |
| International Agency for Res on Cancer | Lyon | 1 | $2.7 million | 0 | $0 |
| University of Pennsylvania | Philadelphia, PA | 1 | $2.6 million | 0 | $0 |
| Medical College of Wisconsin | Milwaukee, WI | 3 | $2.5 million | 0 | $0 |
| ST. Jude Children's Research Hospital | Memphis, TN | 4 | $2.3 million | 0 | $0 |
| Broad Institute, Inc. | Cambridge, MA | 1 | $2.3 million | 0 | $0 |
| Research Inst of Fox Chase Can CTR | Philadelphia, PA | 1 | $2.1 million | 0 | $0 |
| Wistar Institute | Philadelphia, PA | 1 | $1.1 million | 0 | $0 |
| Tulane University of Louisiana | New Orleans, LA | 1 | $1.1 million | 0 | $0 |
| Children's Hosp of Philadelphia | Philadelphia, PA | 1 | $800,000 | 0 | $0 |
| University of Miami School of Medicine | Coral Gables, FL | 1 | $702,046 | 0 | $0 |
| University of Rochester | Rochester, NY | 1 | $655,112 | 0 | $0 |
| University of Minnesota | Minneapolis, MN | 2 | $628,816 | 0 | $0 |
| Washington University | Saint Louis, MO | 1 | $583,092 | 0 | $0 |
| Yale University | New Haven, CT | 1 | $549,899 | 0 | $0 |
| University of Florida | Gainesville, FL | 2 | $468,904 | 0 | $0 |
| Oregon Health & Science University | Portland, OR | 1 | $433,852 | 0 | $0 |
| Vironika, LLC | Wynnewood, PA | 1 | $399,278 | 0 | $0 |
| Emory University | Atlanta, GA | 1 | $357,818 | 0 | $0 |
| Rush University Medical Center | Chicago, IL | 1 | $343,650 | 0 | $0 |
| The Institute of Cancer Research: Royal Cancer Hospital | London | 1 | $230,695 | 0 | $0 |
| University of Utah | Salt Lake City, UT | 2 | $195,600 | 0 | $0 |
| University of Michigan at Ann Arbor | Ann Arbor, MI | 1 | $183,044 | 0 | $0 |
| Fred Hutchinson Cancer Center | Seattle, WA | 1 | $176,000 | 0 | $0 |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 28 | $14,241,876 | 0 | $0 |
| 2024 | 26 | $11,415,742 | 0 | $0 |
| 2023 | 23 | $11,084,515 | 0 | $0 |
| 2022 | 25 | $11,294,451 | 0 | $0 |
| 2021 | 18 | $7,742,748 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
| Open opportunity | Number | Agency | Listing | Closes | Award ceiling | Why it matches |
|---|---|---|---|---|---|---|
| NCI Research Specialist (Clinician Scientist) Award (R50 Clinical Trial Not Allowed) | PAR-27-089 | NIH | 93.396 | November 2, 2026 | Not listed | Same assistance listing 93.396 as 11 awards here |
| NCI Research Specialist Award for Core and Laboratory-based Scientists (R50 Clinical Trial Not Allowed) | PAR-27-088 | NIH | 93.396 | November 20, 2026 | Not listed | Same assistance listing 93.396 as 11 awards here |
| NIH Research Software Engineer (RSE) Award (R50 Clinical Trials Not Allowed) | RFA-OD-24-011 | NIH | 93.396 | December 4, 2026 | Not listed | Same assistance listing 93.396 as 11 awards here |
| Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required) | PAR-24-214 | NIH | 93.396 | January 7, 2027 | $375,000 | Same assistance listing 93.396 as 11 awards here |
| Population Approaches to Reducing Alcohol-related Cancer Risk (R01 Clinical Trial Optional) | PAR-25-221 | NIH | 93.396 | January 7, 2027 | Not listed | Same assistance listing 93.396 as 11 awards here |
| Single Source: Coordinating Center (CC) for the Small Cell Lung Cancer (SCLC) Consortium (U24 Clinical Trial Not Allowed) | PAR-27-009 | NIH | 93.396 | January 25, 2027 | Not listed | Same assistance listing 93.396 as 11 awards here |
| Carcinogen Hazard Assessment Monographs Program (CHAMP) (R01 Clinical Trial Not Allowed) | RFA-CA-28-013 | NIH | 93.396 | February 9, 2027 | $700,000 | Same assistance listing 93.396 as 11 awards here |
| New Approaches for Measuring Brain Changes Across Longer Timespans (R21 Clinical Trial Optional) | PAR-25-272 | NIH | 93.396 | May 7, 2027 | Not listed | Same assistance listing 93.396 as 11 awards here |
| New Approaches for Measuring Brain Changes Across Longer Timespans (R01 Clinical Trial Optional) | PAR-25-279 | NIH | 93.396 | May 7, 2027 | Not listed | Same assistance listing 93.396 as 11 awards here |
| Advanced Development and Sustainment of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) | RFA-CA-28-003 | NIH | 93.396 | June 11, 2027 | $600,000 | Same assistance listing 93.396 as 11 awards here |
| Change of Recipient Organization (Type 7 Parent Clinical Trial Optional) | PA-24-254 | NIH | 93.396 | July 12, 2027 | Not listed | Same assistance listing 93.396 as 11 awards here |
| Successor-in-Interest (Type 6 Parent Clinical Trial Optional) | PA-24-253 | NIH | 93.396 | July 17, 2027 | Not listed | Same assistance listing 93.396 as 11 awards here |
| NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed) | PA-25-080 | NIH | 93.396 | September 7, 2027 | Not listed | Same assistance listing 93.396 as 11 awards here |
| Investigator-Focused Award (Parent R35) | PAR-28-037 | NIH | 93.396 | October 4, 2027 | Not listed | Same assistance listing 93.396 as 11 awards here |
| Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional) | RFA-CA-27-019 | NIH | 93.396 | October 19, 2027 | $300,000 | Same assistance listing 93.396 as 11 awards here |
| NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) | PA-25-301 | NIH | 93.396 | January 7, 2028 | Not listed | Same assistance listing 93.396 as 11 awards here |
| NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Allowed) | PA-25-304 | NIH | 93.396 | January 7, 2028 | Not listed | Same assistance listing 93.396 as 11 awards here |
| NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Required) | PA-25-306 | NIH | 93.396 | January 7, 2028 | Not listed | Same assistance listing 93.396 as 11 awards here |
| Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed) | PAR-24-311 | NIH | 93.396 | January 7, 2028 | $500,000 | Same assistance listing 93.396 as 11 awards here |
| Mechanisms that Impact Cancer Risk after Bariatric Surgery (R01 Clinical Trial Optional) | PAR-25-043 | NIH | 93.396 | January 7, 2028 | $500,000 | Same assistance listing 93.396 as 11 awards here |
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.